Background: Previous research on alexithymia and depression has led to a controversy over whether alexithymia should be viewed as a state-dependent phenomenon or as a stable personality trait. The aim of this 5-year follow-up study was to examine the temporal stability of alexithymia in outpatients suffering from major depression. Methods: The study population comprised 116 (49 male and 67 female) outpatients with major depression. Alexithymic features were assessed with the Toronto Alexithymia Scale (TAS-20) and the degree of depression with the Beck Depression Inventory. The patients were retested after a period of 5 years. Results: Mean alexithymia and depression scores decreased significantly over the 5-year period. Alexithymia and depression were associated with each other, but the high test-retest correlations in the TAS-20 scores indicate relative stability of alexithymia. The three factors of alexithymia behaved differently. Difficulty in identifying feelings and difficulty in describing feelings were associated with alleviation of depressive symptoms, whereas externally oriented thinking was not. Conclusions: Alexithymia seems to be related with the severity of depression in outpatients with major depression, but it also shows relative stability over 5 years. Our findings support the view that the alexithymia construct represents a stable personality trait, but is also a state-dependent phenomenon.

1.
Sifneos PE: The prevalence of alexithymic characteristics in psychosomatic patients. Psychother Psychosom 1973;22:255–262.
2.
Taylor GJ, Bagby RM, Parker JDA: Disorders of Affect Regulation. Cambridge, Cambridge University Press, 1997.
3.
Salminen JK, Saarijärvi S, Äärelä E, Toikka T, Kauhanen J: Prevalence of alexithymia and its association with sociodemographic variables in the general population of Finland. J Psychosom Res 1999;46:75–82.
4.
Honkalampi K, Hintikka J, Tanskanen A, Lehtonen J, Viinamäki H: Depression is strongly associated with alexithymia in the general population. J Psychosom Res 2000;48:99–104.
5.
Salminen JK, Saarijärvi S, Äärelä E, Toikka T: Alexithymia – state or trait? One-year follow-up study of general hospital psychiatric consultation outpatients. J Psychosom Res 1994;681–685.
6.
Honkalampi K, Hintikka J, Saarinen P, Lehtonen J, Viinamäki H: Is alexithymia a permanent feature in depressed patients? Results from a 6-month follow-up study. Psychother Psychosom 2000;69:303–308.
7.
Honkalampi K, Koivumaa-Honkanen H, Tanskanen A, Hintikka J, Lehtonen J, Viinamäki H: Why do alexithymic features appear to be stable? Psychother Psychosom 2001;70:247–253.
8.
Saarijärvi S, Salminen JK, Toikka T: Alexithymia and depression: A 1-year follow-up study in outpatients with major depression. J Psychosom Res 2001;51:729–733.
9.
Taylor GJ, Bagby RM: New trends in alexithymia research. Psychother Psychosom 2004;73:68–77.
10.
Santor DA, Bagby RM, Joffe RT: Evaluating stability and change in personality and depression. J Pers Soc Psychol 1997;73:1354–1362.
11.
Luminet O, Bagby RM, Taylor GJ: An evaluation of the absolute and relative stability of alexithymia in patients with major depression. Psychother Psychosom 2001;70:254–260.
12.
Porcelli P, Bagby M, Taylor GJ, De Garne M, Leandro G, Toderallo H: Alexithymia as a predictor of treatment outcome in patients with functional gastrointestinal disorders. Psychosom Med 2003;65:911–918.
13.
Porcelli P, Affatati V, Bellomo A, De Carne M, Todarello O, Taylor GJ: Alexithymia and psychopathology in patients with psychiatric and functional gastrointestinal disorders. Psychother Psychosom 2004;73:84–91.
14.
Rufer M, Hand I, Braatz A, Alsleben H, Fricke S, Peter H: A prospective study of alexithymia in obsessive-compulsive patients treated with multimodal cognitive-behavioral therapy. Psychother Psychosom 2004;73:101–106.
15.
Marchesi C, Fontò S, Balista C, Cimmino C, Maggini C: Relationship between alexithymia and panic disorder: A longitudinal study to answer an open question. Psychother Psychosom 2005;74:56–60.
16.
Spitzer RL, Williams JBW, Gibbon M, et al: Structured Clinical Interview for DSM-III-R (SCID) I: History, rationale and description. Arch Gen Psychiatry 1992;49:624–629.
17.
Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278–296.
18.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:53–63.
19.
Joukamaa M, Miettunen J, Kokkonen P, Koskinen M, Julkunen J, Kauhanen J, Jokelainen J, Veijola J, Läksy K, Järvelin MR: Psychometric properties of the Finnish 20-item Toronto Alexithymia Scale. Nord J Psychiatry 2001;55:123–127.
20.
Bagby RM, Parker JDA, Taylor GJ: The twenty-item Toronto Alexithymia Scale. I. Item selection and cross validation of the factor structure. J Psychosom Res 1994;38:23–32.
21.
Bagby RM, Taylor GJ, Parker JDA: The twenty-item Toronto Alexithymia Scale. II. Convergent, discriminant, and concurrent validity. J Psychosom Res 1994;38:33–40.
22.
The Classification of Socio-Economic Groups: Handbook of the Central Statistical Office of Finland (in Finnish with an English summary). Helsinki, 1989.
23.
Valera EM, Berenbaum H: A twin study of alexithymia. Psychother Psychosom 2001;70:239–246.
24.
Tabibnia G, Zaidel E: Alexithymia, interhemispheric transfer, and right hemispheric Specialization: A Critical Review. Psychother Psychosom 2005;74:81–92.
25.
Fava GA, Ruini C, Rafanelli C: Psychometric theory is an obstacle to the progress of clinical research. Psychother Psychosom 2004;73:145–148.
26.
Bech P: Modern psychometrics in clinimetrics: Impact on clinical trials of antidepressants. Psychother Psychosom 2004;73:134–138.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.